Effect of enhanced external counterpulsation on circulating CD34+ progenitor cell subsets

Area of Science:

• Cardiovascular Medicine
• Regenerative Medicine
• Hematology

Background:

• Enhanced external counterpulsation (EECP) improves endothelial function, angina, and quality of life in coronary artery disease patients.
• The precise mechanisms behind EECP's clinical benefits remain unclear.
• Investigating the impact of EECP on circulating progenitor cells is crucial for understanding its therapeutic effects.

Purpose of the Study:

• To investigate the effects of EECP on circulating hematopoietic progenitor cells (HPCs) and endothelial progenitor cells (EPCs) in patients with refractory angina.
• To compare HPC and EPC counts in patients undergoing EECP versus control groups.
• To explore the potential role of bone marrow-derived progenitor cells in EECP's mechanism of action.

Main Methods:

• Prospective enrollment of thirteen patients scheduled for EECP treatment.
• Collection of venous blood samples at multiple time points: baseline, mid-treatment, end-of-treatment, and one month post-treatment.
• Quantification of HPCs and EPCs using flow cytometry analysis of buffy coat samples.

Main Results:

• Significant decrease in Canadian Cardiovascular Society (CCS) angina class and increase in Duke Activity Status Index (DASI) functional score post-EECP, sustained at one month.
• Significant increase in circulating CD34+, CD133+, and CD34+/CD133+ progenitor cell counts during EECP treatment.
• Correlation between DASI scores and increased progenitor cell counts (CD34+, CD133+, CD34+/CD133+).

Conclusions:

• EECP treatment significantly increases circulating HPCs, but not EPCs, in patients with refractory angina.
• The observed increase in HPCs correlates with reproducible measures of clinical improvement, including reduced angina and enhanced functional capacity.
• These findings provide the first evidence linking EECP's functional benefits to an increase in circulating progenitor cells.